The Drug Discovery Hub Dortmund (DDHD) started in April 2018 as a new initiative for research of pharmaceutical active ingredients in NRW under the leadership of Univ.-Prof. Dr. Daniel Rauh at the Faculty of Chemistry and Chemical Biology (CCB) of the TU Dortmund. DDHD intends to build a bridge in order to overcome the critical innovation gap between basic academic research and industrial implementation. Early-stage inventions from academic research will be developed successively to lead structures for the pharmaceutical industry. DDHD accomplishes this by concentrating the spread competences of its partners in a sustainably synergistic infrastructure that functions as an incubator for the research of pharmaceutical active ingredients in NRW.
The project comprises within the time frame of three years a volume of up to EUR 11 Million in total. It is funded by the program “Forschungsinfrastrukturen NRW“ of the state NRW and resources from “European Regional Development Fund” (ERDF).
The role of PROvendis is continuous scouting of innovative approaches in all relevant Universities of NRW and to evaluate the approaches in view of IP and market potential. Besides, PROvendis analyses the market survey for the focus of DDHD and assists in public relations. For these challenges, PROvendis has well-established contacts to the scientists of NRW Universities and associated clinics as well as long year experience in the fields of IP Management and IP commercialisation.
Integrated partners of DDHD:
- Max-Planck-Institut für molekulare Physiologie (MPI)
- Leibniz-Institut für Arbeitsforschung an der TU Dortmund (IfADo)
- Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V.
- Taros GmbH & Co. KG
- BioMedizinZentrum Dortmund (BMZ)
- Lead Discovery Center GmbH (LDC)
More information can be found here: https://www.ddhdortmund.de/